Ganymed Pharmaceuticals Ag

Johannes Gutenberg-universität Mainz

Biontech Ag

Astellas Pharma Gmbh

Ganymed Pharmaceuticals Gmbh

Johannes Gutenberg Universität

Other

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

Tron—translationale Onkologie an Der Universitat

Johannes Gutenberg-universität Mainz, Vertreten Durch Den Präsidenten

Dirk Usener

Ugur Sahin

Özlem Türeci

Michael Koslowski

Gunda Brandenburg

Gerd Helftenbein

Volker Schlüter

Harald-Gerhard Geppert

Stefan Fritz

Ozlem Tureci

Christoph Uherek

Anja Kristina Schröder

Phillippe Thiel

Philippe Thiel

Sandra Schneider

Cristoph Uherek

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

Monoclonal antibodies against Claudin-18 for treatment of cancer

Monoclonal antibodies against claudin-18 for treatment of cancer

The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.

Identification of surface associated antigen FLJ31461 for tumor diagnosis and therapy

The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.

Identification of surface-associated antigens for tumor diagnosis and therapy

The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.

Identification of tumor-associated antigens for diagnosis and therapy

An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

Growing community of inventors

Wiesbaden, Germany

Dirk Usener